Piper Sandler Maintains Overweight on Dyne Therapeutics, Raises Price Target to $29
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Dyne Therapeutics (NASDAQ:DYN) and increased the price target from $27 to $29.
March 06, 2024 | 2:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler maintains an Overweight rating on Dyne Therapeutics and raises the price target from $27 to $29.
The upgrade in the price target by a reputable analyst like Edward Tenthoff signals a strong confidence in Dyne Therapeutics' future performance. This is likely to positively influence investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100